Journal of Pharmacogenomics & Pharmacoproteomics

Cristina M Fajardo

Publications

• Research Article
  Polymorphisms in Genes Encoding Metalloproteinase 9 and Lymphotoxin-Alpha can Influence Warfarin Treatment
  Author(s): Jéssica B Borges, Thiago DC Hirata, Alvaro Cerda, Cristina M Fajardo, Raony CC Cesar, João ID França, Jéssica C Santos, Hui-Tzu L Wang, Lara R Castro, Marcelo F Sampaio, Rosario DC Hirata, Mario H Hirata Jéssica B Borges, Thiago DC Hirata, Alvaro Cerda, Cristina M Fajardo, Raony CC Cesar, João ID França, Jéssica C Santos, Hui-Tzu L Wang, Lara R Castro, Marcelo F Sampaio, Rosario DC Hirata, Mario H Hirata
  
  Objectives: Warfarin treatment is influenced by environmental and genetic factors. The influence of polymorphisms in genes encoding metalloproteinase 9 (MMP9), lymphotoxin-alpha (LTA) andTNFSF14 (LIGHT), related to the inflammatory process of coronary artery disease, on warfarin dose and time to reach target was investigated in this study. Methods: Outpatients on warfarin treatment (n=227), 20 to 92 years, were enrolled at the Institute Dante Pazzanese of Cardiology (IDPC). Genomic DNA was obtained from peripheral whole blood to evaluate MMP9 rs17576 (Gln279Arg, A>G), LTA rs1041981 (Thr60Asn, C>A) and rs909253 (c.252T>C) and TNFSF14rs2291668 (c.147C>T) and rs344560 (Lys214Glu, G>A) polymorphisms by pyrosequencing in Q24PyroMark. Results: The patients carrying MMP9 rs17576GG genotype were more likely to require a lower warfarin weekly do.. View More»
  DOI: 10.4172/2153-0645.1000143

  Abstract PDF